Profile
NTRB NVO VRTX REGN MRNA SGEN
Company Name Nutriband Inc. Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Moderna, Inc. Seagen Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $83.43M $575.53B $127.80B $116.89B $46.80B $43.15B
Employees 0.01K 66.02K 5.40K 13.68K 5.60K 3.26K
CEO Mr. Gareth Sheridan Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. Stephane Bancel Mr. David R. Epstein B.Sc., M.B.A.
Ratings
NTRB NVO VRTX REGN MRNA SGEN
Quant Rating Score 2 3 4 4 1 3
Quant Rating Sell Neutral Buy Buy Strong Sell Neutral
Trading
NTRB NVO VRTX REGN MRNA SGEN
Last Close $7.56 $126.73 $495.26 $1078.63 $122.11 $228.74
High 52 $9.25 $199.54 $495.91 $1100.05 $166.61 $228.9
Low 52 $1.93 $87.78 $340.48 $732.12 $69.51 $191.57
Price vs. 52 Week High -18.27 % -36.49 % -0.13 % -1.95 % -26.71 % -0.07 %
Price vs. 52 Week Low 291.71 % 44.37 % 45.46 % 47.33 % 75.67 % 19.4 %
Total Return
NTRB NVO VRTX REGN MRNA SGEN
1 Month Return 41.57 % -12.29 % 4.81 % 2.64 % 0.77 % 0 %
3 Month Return 112.96 % -0.09 % 24.6 % 22.13 % 13.1 % 0 %
6 Month Return 185.28 % 17.27 % 15.13 % 14.74 % 19.94 % 0 %
9 Month Return 258.29 % 35.54 % 39.4 % 39.15 % 69.81 % 6.59 %
YTD Return 225.86 % 22.5 % 21.72 % 22.81 % 22.79 % 0 %
1 Year Return 63.28 % -19.11 % 41.65 % 44.85 % 3.04 % 19.4 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
NTRB NVO VRTX REGN MRNA SGEN
Dividend Yield Percentage (TTM) - 0.16 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) -65.27 % 1.1 % 8.49 % 6.2 % -3.65 % -3.35 %
Dividend Per Share (TTM) - 0.2 % - - - -
Payout Ratio (TTM) - 47.03 % - - - -
Growth
NTRB NVO VRTX REGN MRNA SGEN
Asset Growth -20.51 % 30.35 % 25.23 % 13.23 % -28.74 % -1.21 %
Gross Profit Growth 9.13 % 32.32 % 9.25 % 6.49 % -85.12 % 22.93 %
Revenue Growth 0.27 % 31.26 % 10.17 % 7.76 % -64.94 % 24.65 %
Revenue 3 Year 87.04 % 90.51 % 59.87 % 55.67 % 2356.27 % 91.84 %
Revenue 5 Year 567.42 % 124.2 % 218.58 % 110.3 % 1070.62 % 215.48 %
Revenue 10 Year - 66.11 % 608.27 % 549.62 % 6447.35 % 494.04 %
EBIT Growth -17.46 % 37.11 % -12.94 % -14.6 % -145 % 10.13 %
Net Income Growth -14.02 % 50.71 % 8.96 % -8.87 % -156.37 % 9.51 %
Net Income 3 Yeari Growth Per Share -44.49 % 106.79 % 34.59 % 13.48 % -529.9 % -764.83 %
Net Income 5 Yeari Growth Per Share -29.27 % 133.86 % 70.33 % 74.02 % -160.17 % -276.93 %
Net Income 10 Yeari Growth Per Share -1044169.94 % 98.61 % 809.6 % 871.12 % -2046.03 % -624.16 %
Operating Income Growth -17.46 % 37.11 % -12.94 % -14.6 % -145 % 10.13 %
Operating Cash Flow Growth (CFG) -18.09 % 38.06 % -14.35 % -8.39 % -162.6 % 9.07 %
Operating 3 Year CFG -905.16 % 118.29 % 9.63 % 76.95 % -253.56 % -148.34 %
Operating 5 Year CFG -150.51 % 163.51 % 174.78 % 125.17 % -100.11 % -195.86 %
Operating 10 Year CFG - 150.92 % 6084.35 % 713.56 % -4698.89 % -2622.09 %
EPS Growth -21.05 % 52.28 % 8.33 % -8.54 % -158.15 % 10.81 %
EPS Diluted Growth -21.05 % 52.37 % 8.35 % -9.03 % -161.39 % 10.81 %
Book Value Per Share -20.13 % 29 % 25.58 % 15.03 % -25.28 % -9.83 %
Share Holder 3 Year Equity Growth Per Share -23.37 % 75.22 % 104.06 % 137.56 % 439.94 % 33.92 %
Share Holder 5 Year Equity Growth Per Share 110.19 % 121.9 % 291.14 % 219.1 % 92.24 % 220.81 %
Share Holder 10 Year Equity Growth Per Share 42843.95 % 49.62 % 1030.79 % 1286.9 % 1519.81 % 691.19 %
Dividend Per Share Growth - 26.89 % - - - -
Dividend 3 Year Growth Per Share - 64.4 % - - - -
Dividend 5 Year Growth Per Share - 80.03 % - - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth 29.86 % 4.74 % 44.1 % 0.06 % 3.58 % -23.28 %
Free Cash Flow Growth -16.72 % 9.17 % -16.47 % -17.11 % -183.5 % 3.67 %
Updated On 31 Jan 2024 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022
Profitability
NTRB NVO VRTX REGN MRNA SGEN
Gross Profit Margin TTM 38.82 % 84.65 % 86.86 % 87.16 % 21.77 % 75.4 %
Return on Assets TTM -42.02 % 29.87 % 16.81 % 11.22 % -35.67 % -20.64 %
Return on Equity TTM -78.61 % 91.82 % 23.61 % 15.15 % -41.83 % -28.06 %
Return on Capital Employed TTM -41.81 % 82.5 % 20.67 % 12.53 % -35.81 % -29.5 %
Net Income Per EBT TTM 100 % 79.81 % 84.31 % 95.44 % 124.28 % 101.53 %
EBT Per Ebit TTM 110.88 % 101.7 % 114.62 % 104.74 % 93.44 % 93.47 %
EBIT Per Revenue TTM -284.77 % 45.03 % 40.85 % 29.46 % -99.69 % -34.37 %
Cash Flow To Debt Ratio TTM -684.12 % 346.88 % 546.79 % 238.94 % -232.98 % -475.96 %
Receivables Turnover TTM 23.69 3.87 5.68 2.51 13.32 3.64
Payables Turnover TTM 1.24 2.88 3.81 2.51 22.04 2.52
Inventory Turnover TTM 7.32 1.12 1.65 0.62 13.67 1.07
Fixed Asset Turnover TTM 264.05 % 248.64 % 685.31 % 310.02 % 186.78 % 471.71 %
Asset Turnover TTM 13.31 % 81.71 % 42.57 % 38.12 % 30.81 % 63.3 %
Operating Cash Flow Per Share TTM -0.39 20.95 15.27 43.96 -7.54 -2.87
Free Cash Flow Per Share TTM -0.4 11.28 13.48 36.87 -9.61 -3.73
Cash Per Share TTM 91.13 % 208.61 % 3939.31 % 9758.35 % 2235.6 % 657.5 %
Operating Cash Flow Sales Ratio TTM -179.06 % 38.24 % 38.74 % 36.17 % -55.91 % -23.48 %
Free Cash Flow Operating Cash Flow Ratio TTM 101.53 % 53.85 % 88.22 % 83.87 % 127.41 % 129.82 %
Cash Flow Coverage Ratios TTM -684.12 % 346.88 % 546.79 % 238.94 % -232.98 % -475.96 %
Price To Free Cash Flows Ratio TTM -22.75 78.64 36.73 29.41 -12.74 -61.54
Price To Operating Cash Flows Ratio TTM -19.17 41.59 32.42 24.54 -16.19 -79.67
Price Cash Flow Ratio TTM -19.17 41.59 32.42 24.54 -16.19 -79.67
Income Statement (TTM)
NTRB NVO VRTX REGN MRNA SGEN
Revenue $0B $232.26B $9.84B $13.12B $6.75B $1.96B
Gross Profit $0B $196.5B $8.58B $11.3B $2.06B $1.55B
Gross Profit Ratio 39.27% 84.6% 87.17% 86.16% 30.52% 79.1%
EBITDA $-0B $112.94B $3.93B $5.13B $-3.21B $-0.62B
Net Income $-0.01B $83.68B $3.62B $3.95B $-4.71B $-0.61B
EPS Diluted -0.69 18.62 13.89 34.77 -12.34 -3.3
Balance Sheet (MRQ)
NTRB NVO VRTX REGN MRNA SGEN
Long Term Debt $0B $20.53B $0.72B $2.7B $1.22B $0.04B
Total Liabilities $0B $207.93B $5.15B $7.11B $4.57B $0.87B
Total Equity $0.01B $106.56B $17.58B $25.97B $13.85B $2.8B
Total Investments $0B $17.5B $3.45B $13.51B $4.68B $1.42B
Total Debt $0B $27.01B $0.81B $2.7B $1.24B $0.04B
Total Assets $0.01B $314.49B $22.73B $33.08B $18.43B $3.67B
Cash Flow Statement (TTM)
NTRB NVO VRTX REGN MRNA SGEN
Net Income $-0.01B $83.68B $3.62B $3.95B $-4.71B $-0.61B
Inventory $0B $-7.42B $-0.32B $-0.27B $0.75B $-0.23B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0B $108.91B $3.54B $4.59B $-3.12B $-0.45B
Capital Expenditure $-0B $-38.9B $-0.26B $-0.93B $-0.71B $-0.08B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 1.58
ABCL AbCellera Biologics Inc. 3.26
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.1
ABIO ARCA biopharma, Inc. 3.14
ABOS Acumen Pharmaceuticals, Inc. 3.48
ABSI Absci Corporation 4.48
ABUS Arbutus Biopharma Corporation 3.9
ABVC ABVC BioPharma, Inc. 0.7489
ABVX Abivax SA American Depositary Shares 11.86
ACAD ACADIA Pharmaceuticals Inc. 19.14
ACER Acer Therapeutics Inc. 0.9
ACET Adicet Bio, Inc. 1.59
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 0.8288
ACHV Achieve Life Sciences, Inc. 4.925
ACIU AC Immune SA 3.91
ACLX Arcellx, Inc. 64.41
ACRV Acrivon Therapeutics, Inc. Common Stock 8.86
ACST Acasti Pharma Inc. 2.76
ETFs With Exposure to NTRB
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 269.69
VXF Vanguard Extended Market Index Fund 0 178.79
IWC iShares Micro-Cap ETF 0.01 129.25
VTSAX Vanguard Total Stock Market Index Fund 0 131.27
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 135.6
VITSX Vanguard Total Stock Market Index Fund 0 131.29
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 135.6
VEMPX Vanguard Extended Market Index InstlPlus 0 334.63
VSMPX Vanguard Total Stock Mkt Idx Instl Pls 0 246.27
Unlock